RxDoctor Payments Data

Randall Wooley, MD

Internal Medicine · Dallas, TXNPI 1639154966

Payments from drug & device makers

$617in general payments, 2019–2025

Across 16 payments — averaging $38.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aurinia Pharma U.S., Inc.$154
  • Novartis$117
  • Cleerly, Inc.$68
  • Inari Medical, Inc.$60
  • Stryker$60
  • GSK$48
  • plus $111 from 6 others

What the payments were for

  • Consulting fees$142%
  • Food & beverage$60398%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$617 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$290,598
Medicare patients
660
Services billed
6,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide130$145,225
EliquisApixaban100$82,090
XareltoRivaroxaban38$38,767
TrulicityDulaglutide36$37,606
JardianceEmpagliflozin41$32,079
DescovyEmtricitabine/Tenofov Alafenam13$28,057
JanuviaSitagliptin Phosphate22$21,478
FarxigaDapagliflozin Propanediol21$20,455
RybelsusSemaglutide16$16,174
MounjaroTirzepatide15$15,395
BelsomraSuvorexant34$14,640
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$13,737
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,107
MyrbetriqMirabegron21$10,855
InvokanaCanagliflozin13$9,787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$48$18,93333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →